Piper Sandler initiated coverage of Summit Therapeutics (SMMT) with a Neutral rating and $21 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating
- Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments
- Summit going concern language ‘non-issue,’ says Citi
- Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’
- Summit Therapeutics falls -12.5%